These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18754876)

  • 1. Over-expression of cysteine proteinase inhibitor cystatin 6 promotes pancreatic cancer growth.
    Hosokawa M; Kashiwaya K; Eguchi H; Ohigashi H; Ishikawa O; Furihata M; Shinomura Y; Imai K; Nakamura Y; Nakagawa H
    Cancer Sci; 2008 Aug; 99(8):1626-32. PubMed ID: 18754876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities.
    D'Costa ZC; Higgins C; Ong CW; Irwin GW; Boyle D; McArt DG; McCloskey K; Buckley NE; Crawford NT; Thiagarajan L; Murray JT; Kennedy RD; Mulligan KA; Harkin DP; Waugh DJ; Scott CJ; Salto-Tellez M; Williams R; Mullan PB
    Oncotarget; 2014 Mar; 5(6):1609-20. PubMed ID: 24742492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas.
    Qiu J; Ai L; Ramachandran C; Yao B; Gopalakrishnan S; Fields CR; Delmas AL; Dyer LM; Melnick SJ; Yachnis AT; Schwartz PH; Fine HA; Brown KD; Robertson KD
    Lab Invest; 2008 Sep; 88(9):910-25. PubMed ID: 18607344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EphA4 receptor, overexpressed in pancreatic ductal adenocarcinoma, promotes cancer cell growth.
    Iiizumi M; Hosokawa M; Takehara A; Chung S; Nakamura T; Katagiri T; Eguchi H; Ohigashi H; Ishikawa O; Nakamura Y; Nakagawa H
    Cancer Sci; 2006 Nov; 97(11):1211-6. PubMed ID: 16965393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gamma-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor pi subunit.
    Takehara A; Hosokawa M; Eguchi H; Ohigashi H; Ishikawa O; Nakamura Y; Nakagawa H
    Cancer Res; 2007 Oct; 67(20):9704-12. PubMed ID: 17942900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer.
    Pulukuri SM; Gorantla B; Knost JA; Rao JS
    Oncogene; 2009 Aug; 28(31):2829-38. PubMed ID: 19503093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4.
    Takehara A; Eguchi H; Ohigashi H; Ishikawa O; Kasugai T; Hosokawa M; Katagiri T; Nakamura Y; Nakagawa H
    Cancer Sci; 2006 Nov; 97(11):1191-7. PubMed ID: 16918991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice.
    Jandaghi P; Najafabadi HS; Bauer AS; Papadakis AI; Fassan M; Hall A; Monast A; von Knebel Doeberitz M; Neoptolemos JP; Costello E; Greenhalf W; Scarpa A; Sipos B; Auld D; Lathrop M; Park M; Büchler MW; Strobel O; Hackert T; Giese NA; Zogopoulos G; Sangwan V; Huang S; Riazalhosseini Y; Hoheisel JD
    Gastroenterology; 2016 Dec; 151(6):1218-1231. PubMed ID: 27578530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells.
    Momeny M; Alishahi Z; Eyvani H; Esmaeili F; Zaghal A; Ghaffari P; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Cell Oncol (Dordr); 2020 Feb; 43(1):81-93. PubMed ID: 31512195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystatin F as a key family 2 cystatin subunit and prognostic biomarker for early‑stage pancreatic ductal adenocarcinoma.
    Yang C; Yu T; Liu Z; Ye X; Liao X; Wang X; Han C; Zhu G; Qin W; Peng T
    Oncol Rep; 2019 Jul; 42(1):79-90. PubMed ID: 31059105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The candidate tumor suppressor CST6 alters the gene expression profile of human breast carcinoma cells: down-regulation of the potent mitogenic, motogenic, and angiogenic factor autotaxin.
    Song J; Jie C; Polk P; Shridhar R; Clair T; Zhang J; Yin L; Keppler D
    Biochem Biophys Res Commun; 2006 Feb; 340(1):175-82. PubMed ID: 16356477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.
    Chen YW; Hsiao PJ; Weng CC; Kuo KK; Kuo TL; Wu DC; Hung WC; Cheng KH
    BMC Cancer; 2014 Mar; 14():181. PubMed ID: 24625091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of angiotensin II type 2 receptor (AT2R) signaling in human pancreatic ductal adenocarcinoma (PDAC): a novel AT2R agonist effectively attenuates growth of PDAC grafts in mice.
    Ishiguro S; Yoshimura K; Tsunedomi R; Oka M; Takao S; Inui M; Kawabata A; Wall T; Magafa V; Cordopatis P; Tzakos AG; Tamura M
    Cancer Biol Ther; 2015; 16(2):307-16. PubMed ID: 25756513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophage polarization in pancreatic carcinoma: role of heparanase enzyme.
    Hermano E; Meirovitz A; Meir K; Nussbaum G; Appelbaum L; Peretz T; Elkin M
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25326645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulated expression of IL‑28RA is involved in the pathogenesis of pancreatic ductal adenocarcinoma.
    Liu L; Qi Y; Huang D; Xu Y; Li M; Hong Z; Gu Y; Jia B; Luo X; Zhang S; Zhang S
    Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34195850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The human cystatin M/E gene (CST6): exclusion candidate gene for harlequin ichthyosis.
    Zeeuwen PL; Dale BA; de Jongh GJ; van Vlijmen-Willems IM; Fleckman P; Kimball JR; Stephens K; Schalkwijk J
    J Invest Dermatol; 2003 Jul; 121(1):65-8. PubMed ID: 12839564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells.
    Haselmann V; Kurz A; Bertsch U; Hübner S; Olempska-Müller M; Fritsch J; Häsler R; Pickl A; Fritsche H; Annewanter F; Engler C; Fleig B; Bernt A; Röder C; Schmidt H; Gelhaus C; Hauser C; Egberts JH; Heneweer C; Rohde AM; Böger C; Knippschild U; Röcken C; Adam D; Walczak H; Schütze S; Janssen O; Wulczyn FG; Wajant H; Kalthoff H; Trauzold A
    Gastroenterology; 2014 Jan; 146(1):278-90. PubMed ID: 24120475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression.
    Ai L; Kim WJ; Kim TY; Fields CR; Massoll NA; Robertson KD; Brown KD
    Cancer Res; 2006 Aug; 66(16):7899-909. PubMed ID: 16912163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.